GLP-1 Drugs Linked to Lower Death Risk in Serious Mental Illness
Source Summary
A target trial emulation study of 195,184 propensity score-matched adults found that starting a GLP-1 receptor agonist was associated with significantly lower risks of death and cardiovascular events in people with serious mental illness. The research suggests GLP-1 drugs may help address the elevated mortality gap observed in this population.
Why it matters
People with serious mental illness face significantly higher mortality rates, and this finding suggests GLP-1 drugs may offer a therapeutic pathway to reduce both death and cardiovascular complications in this vulnerable population.
